Note: this article is informational and is not medical advice; treatment decisions belong with a hepatologist who can review liver labs, viral load and individual risk.
FDA Approves Hibsago, the First Treatment Aimed at a Functional Cure for Hepatitis B
The Hibsago FDA approval arrived on October 20, 2026, when GSK announced that the agency had cleared bepirovirsen for chronic hepatitis B, the first therapeutic aimed squarely at a functional cure rather than lifelong viral suppression for eligible patients. The drug is approved for adults without cirrhosis who are already on at least six months of nucleos(t)ide analog therapy with suppressed HBV DNA and whose surface antigen (HBsAg) level is at or below 3,000 IU/mL on an FDA-authorized test. About 1.7 million people in the United States live with chronic hepatitis B, and until now the standard of care suppresses the virus indefinitely without clearing it.
Key Takeaways:
- – FDA approved Hibsago (bepirovirsen) on October 20, 2026 for adults without cirrhosis on NrtI therapy for at least six months with suppressed HBV DNA and HBsAg at 3,000 IU/mL or below.
- – In pooled phase 3 B-Well data, 19% of treated adults (233 of 1,220) achieved a functional cure versus none of the placebo arm; the standard of care alone typically achieves under 1% after a year.
- – Among patients with HBsAg at or below 1,000 IU/mL, roughly 45% of diagnosed cases globally, the functional-cure rate was 26%.
- – The drug carries a boxed warning for on-treatment hepatic flares and thrombocytopenia, with platelet and liver-enzyme monitoring required throughout.
- – A six-month course is given by injection, with the option of self-administration after the first dose.
What the B-Well Trial Data Shows
The approval rests on the pooled B-Well phase 3 program: two global, randomized, double-blind, placebo-controlled trials across 29 countries. Six months of bepirovirsen achieved a functional-cure rate of 19%, 233 of 1,220 participants, against 0 of 614 on placebo. Functional cure, the marker the whole field chases, is defined as undetectable HBV DNA and undetectable HBsAg for at least 24 weeks after stopping all treatment, meaning the immune system holds the disease down on its own. Depth of response tracked baseline surface antigen levels: at 1,000 IU/mL or below, 26% achieved functional cure (200 of 768), and exploratory analyses showed 49% of the overall population reached HBsAg levels of 100 IU/mL or under by week 72, a range associated in the medical literature with better immune control. Safety coverage matters for context: chronic hepatitis B accounts for roughly 56% of all liver cancer cases worldwide, so any therapy that durably clears surface antigen has cancer-prevention stakes, a case the Hepatitis B Foundation underscored in welcoming the decision.
Who Actually Qualifies
The label carve-outs are strict, and they define the drug’s practical reach. Hibsago is only for adults without cirrhosis, on nucleos(t)ide therapy for at least six months, with fully suppressed HBV DNA, and with measured HBsAg at or below 3,000 IU/mL using an FDA-authorized test. Patients with any degree of hepatic impairment or cirrhosis are contraindicated, as are patients whose platelet count is under 100,000 per microliter before treatment. Physicians will quantitative-test surface antigen up front, because the 3,000 cutoff separates responders from the rest: someone at 400 IU/mL sits in the highest-response subgroup, while someone at 2,900 counts as eligible but with lower expected odds. GSK licensed bepirovirsen from Ionis, and both companies have regulatory decisions pending in additional countries, so the eligible population expands only as those reviews conclude.
The Boxed Warning Explained
The FDA approved the drug with a boxed warning, the agency’s strongest safety flag, covering two named risks. On-treatment hepatic flares are marked rises in the liver enzyme ALT, in some cases 20 to 40 times the upper limit of normal, mostly appearing within the first twelve weeks and generally resolving when the drug is interrupted or stopped. Thrombocytopenia is the second: sudden, unpredictable drops in platelets that can be life-threatening, which is why platelet counts must be checked before the first dose and monitored weekly, with permanent discontinuation below 50,000. The label also flags a gradual decline in kidney filtration (eGFR) that is usually reversible after discontinuation, and warns against use in patients coinfected with hepatitis D. Separately, the label requires frequent monitoring for at least one year if nucleos(t)ide therapy is stopped after the course, because severe hepatitis flares can occur then. In plain terms: the upside is a cure attempt, the cost is hands-on lab monitoring by a specialist.
Why a 19% Rate Restructures the Field
Nineteen percent sounds modest until it is compared with what came before. Standard suppressive therapy, nucleos(t)ide analogs taken indefinitely, reaches a functional cure at a rate the GSK release places under 1% after a year of treatment. Interferon approaches have helped some patients but carry a heavy side-effect burden. Against that baseline, one in five eligible adults stopping all medication within six months, with self-administration possible after the first dose, moves functional cure from pathology-lab goal to clinical agenda. Hepatologists quoted in coverage, including Dr. Norah Terrault of USC Keck, called it the start of a new era for a disease where a generation of drug development successfully suppressed HBV DNA but rarely cleared surface antigen, which is the true obstacle to calling anyone cured.
What Happens Next
Three threads are now live. First, access: pricing and payer coverage have not been published in the coverage reviewed here, and with a specialist-administered injectable and required monitoring, reimbursement grids will decide how quickly the eligible group in the United States, roughly 1.7 million people, gets treated. Expect insurers to build prior-authorization templates around the exact label criteria: cirrhosis-free, six months on NrtI, suppressed DNA, quantified HBsAg. Second, patient selection research will sharpen, because adverse-event management depends on catching flares and platelet drops early, and the monitoring cadence in the label effectively writes the protocol US hepatologists will follow. Third, the regulatory pipeline continues: GSK says decisions are anticipated in coming months across other geographies, and Hibsago’s first global approval came in Japan in August 2026, making the US the second market. For patients, the move this week is not to self-refer for injections; it is to ask a hepatologist for a quantitative HBsAg test, because that one number determines whether this path even opens.
Frequently Asked Questions
Who qualifies for Hibsago?
Adults without cirrhosis who have been on nucleos(t)ide therapy for at least six months, have suppressed HBV DNA, and have hepatitis B surface antigen measured at 3,000 IU/mL or below on an FDA-authorized test.
What is a functional cure for hepatitis B?
It means HBV DNA and the surface antigen (HBsAg) are undetectable for at least 24 weeks after stopping all treatment, indicating the immune system controls the virus without medication.
How well does bepirovirsen work?
In pooled phase 3 B-Well trials, 19% of treated adults achieved functional cure within six months (233 of 1,220, versus none in the placebo group), and 26% among those whose starting surface antigen was at or below 1,000 IU/mL.
Sources:
- https://finance.yahoo.com/healthcare/articles/hibsago-bepirovirsen-approved-us-treatment-235800297.html
- https://www.hcplive.com/view/fda-approves-bepirovirsen-for-chronic-hepatitis-b
- https://www.ajmc.com/view/bepirovirsen-for-chronic-hepatitis-b-receives-breakthrough-therapy-designation-priority-review
- https://www.hepb.org/news-and-events/news/bepirovirsen/
